Creasy and Resnik's Maternal-Fetal Medicine, 9th Edition

If you deliver babies, manage high-risk pregnancies, or study maternal-fetal medicine, this is the standard against which everything else is measured. Nine editions in, it remains the field's most cited synthesis of evidence on complicated pregnancy. General readers with a serious stake in a difficult pregnancy—patients, partners, doulas who want depth—will find it dense but authoritative.

1. 1Ch. 30-31 (Preterm Birth)

   Preterm birth is a syndrome, not one disease

   A woman arrives at 29 weeks with regular contractions and a shortened cervix. One textbook chapter would once have called it 'preterm labor' and treated it one way. Creasy's framework insists she could be one of several distinct patients: infection-driven, vascular, stress-triggered, mechanical. The clinician's job is to figure out which, because the treatment differs.

   The idea

   The field moved from treating preterm labor as a single entity to recognizing multiple pathways—infection, uteroplacental ischemia, cervical insufficiency, maternal stress—that converge on the same endpoint. This explains why a single magic-bullet prevention strategy kept failing: you can't stop four different diseases with one drug. Screening and treatment must match the pathway.

   Try this: If you're pregnant and high-risk, ask your clinician which specific preterm-birth pathway applies to you—not just your generic risk score.

2. 2Ch. 30 (Preterm Birth screening)

   Cervical length is the vital sign of preterm risk

   A routine midtrimester ultrasound measures something most patients never think to ask about: the cervix. A short cervix at the midpoint of pregnancy turns out to be one of the strongest predictors of delivering early. The measurement is cheap, quick, and already part of the anatomy scan most women get anyway.

   The idea

   The cervix functions as a measurable warning light. Transvaginal measurement in the midtrimester identifies women who need interventions—progesterone, cerclage, closer surveillance—before contractions ever start. The surprise is how ordinary the test is: same machine, same visit, one extra measurement that changes management.

   Try this: At your anatomy scan, ask for the cervical length number and what it means for your specific risk.

3. 3Ch. 40 (Hypertensive Disorders)

   Preeclampsia is a two-stage disease of the placenta

   Weeks before a woman's blood pressure rises, the trouble has already begun in the placenta. Poor invasion of the spiral arteries sets the stage; the maternal syndrome—hypertension, proteinuria, organ dysfunction—follows later. By the time symptoms appear, the disease is advanced.

   The idea

   Preeclampsia is best understood as a placental disease with maternal symptoms. The first stage is silent and placental; the second is the clinical syndrome everyone recognizes. This two-stage model explains why prevention efforts target early placentation (aspirin, surveillance) rather than waiting for blood pressure to climb, and why delivery remains the only cure.

   Try this: If you have risk factors (first pregnancy, prior preeclampsia, chronic hypertension), ask about low-dose aspirin and a surveillance plan early.

4. 4Ch. 31 (Preterm Birth management)

   Steroids before preterm delivery save more lives than almost anything else

   A woman at 30 weeks is likely to deliver within days. Before anything else, she gets a course of antenatal corticosteroids. The treatment accelerates fetal lung maturity and reduces neonatal death, respiratory distress, and intraventricular hemorrhage. It is among the highest-value interventions in all of obstetrics.

   The idea

   One of the most replicated findings in perinatal medicine: a short course of steroids before anticipated preterm birth dramatically improves neonatal outcomes. The intervention is cheap, fast, and works even at the edge of viability. The ongoing debates are about timing, repeat courses, and how late is too late—not whether it works.

   Try this: If preterm delivery seems possible, confirm steroids are planned and ask about the timing window.

5. 5Ch. 35 (Diabetes)

   Diabetes in pregnancy is a glucose-threshold problem

   A routine glucose screen at 24-28 weeks sorts pregnancies into those where maternal hyperglycemia raises fetal and neonatal risk and those where it doesn't. The thresholds come from large outcome studies linking specific glucose levels to complications like macrosomia and neonatal hypoglycemia.

   The idea

   Gestational diabetes is defined by where on the glucose-outcome curve risk becomes unacceptable, not by an arbitrary lab cutoff. The diagnostic thresholds were chosen because below them, outcomes look like the general population; above them, complications rise. Treatment—diet, monitoring, insulin when needed—aims to bring maternal glucose back under that risk threshold.

   Try this: Know your glucose screen result and the threshold your provider uses to diagnose gestational diabetes.

6. 6Ch. 42 (Obstetric Hemorrhage)

   Placenta accreta spectrum is a planned-emergency problem

   A woman with a prior cesarean and a placenta previa on this pregnancy is at sharply elevated risk of placenta accreta—placental tissue invading the uterine wall. Undetected, it can cause catastrophic hemorrhage at delivery. Detected, it becomes a logistics problem: imaging, blood bank coordination, a team assembled in advance.

   The idea

   The rise in cesarean rates made placenta accreta spectrum a modern epidemic. The management principle is that outcomes improve dramatically when the diagnosis is made before delivery and the birth happens in a center with the right team and blood products. The lesson generalizes: in obstetric hemorrhage, preparation beats reaction.

   Try this: If you've had a prior cesarean and now have a previa or low-lying placenta, ask specifically about accreta imaging and delivery planning.

7. 7Ch. 50 (Fetal Therapy)

   Fetal surgery: from science fiction to standard of care for a few conditions

   For a handful of fetal conditions—twin-twin transfusion syndrome, spina bifida, certain lung lesions—operating on the fetus before birth now outperforms waiting. Randomized trials shifted some procedures from experimental to indicated. The window between 'technically possible' and 'clearly beneficial' took decades of trial data to close.

   The idea

   Open fetal surgery and fetoscopic procedures are now evidence-based options for a short list of diagnoses. The principle that made it work: treat the fetus only when the natural history untreated is worse than the risks of the operation, and prove it with randomized trials. Most fetal conditions still don't qualify—the discipline is in the narrowness.

   Try this: For any fetal anomaly diagnosis, ask whether an in-utero treatment exists and what the trial evidence says.

8. 8Ch. 45 (Multiple Gestation)

   Twin pregnancies are a different disease

   A twin pregnancy is not a singleton pregnancy twice. Risks of preterm birth, preeclampsia, growth restriction, and perinatal loss are all elevated, and they differ sharply by chorionicity—whether the twins share a placenta. Monochorionic twins carry risks dichorionic twins never face.

   The idea

   Chorionicity is the single most important piece of information in a twin pregnancy, and it must be determined early by ultrasound. Shared placentas create risks—twin-twin transfusion, selective growth restriction—that have no singleton analogue. Management, surveillance intensity, and delivery timing all flow from this one early determination.

   Try this: If you're carrying twins, ask at the first ultrasound whether they're monochorionic or dichorionic and what that means for surveillance.

9. 9Ch. 42 (Obstetric Hemorrhage)

   Postpartum hemorrhage kills by arithmetic, not mystery

   A postpartum hemorrhage protocol treats bleeding as a logistics race: quantify loss, activate a response, replace products in ratio, find the source. The interventions are unglamorous—uterotonics, tranexamic acid, balloon tamponade, escalation to surgery. What saves lives is having the sequence drilled before the emergency.

   The idea

   Hemorrhage deaths are usually deaths of delay and disorganization, not of unknown medicine. The evidence behind protocols—quantified blood loss, early activation, balanced resuscitation, tranexamic acid—shows that systematic response outperforms heroic improvisation. Simulation and drills are part of the treatment.

   Try this: If you're delivering at a given hospital, ask whether it has a formal obstetric hemorrhage protocol and does drills.

10. 10Ch. 39 (Gastrointestinal complications)

    Intrahepatic cholestasis: itching that matters

    A woman in the third trimester develops intense itching of palms and soles, no rash. The textbook flags intrahepatic cholestasis of pregnancy, confirmed by elevated bile acids. The stakes are fetal: stillbirth risk rises with disease severity, which shapes decisions about surveillance and timing of delivery.

    The idea

    Severe pruritus in late pregnancy is a symptom worth taking seriously, not a nuisance. Bile acid levels correlate with fetal risk and guide management. The condition resolves after delivery but recurs in subsequent pregnancies, so the diagnosis matters beyond this pregnancy.

    Try this: Report persistent palm-and-sole itching in late pregnancy to your obstetrician and ask about a bile acid test.

11. 11Ch. 38 (Endocrine disorders)

    Thyroid disease in pregnancy has pregnancy-specific reference ranges

    A woman's TSH comes back 'abnormal' by nonpregnant lab standards. In pregnancy, that may be normal: hCG suppresses TSH in the first trimester, and reference ranges shift by trimester. Treating her by nonpregnant ranges risks overdiagnosis and unnecessary levothyroxine.

    The idea

    Pregnancy changes thyroid physiology enough that lab interpretation requires trimester-specific ranges. The clinical stakes run both directions: untreated overt hypothyroidism harms fetal neurodevelopment, while overtreating subclinical cases adds cost and anxiety without proven benefit. The skill is knowing which range applies and when.

    Try this: If you're tested for thyroid function in pregnancy, ask whether your lab uses trimester-specific reference ranges.

12. 12Ch. 47 (Recurrent pregnancy loss)

    Recurrent pregnancy loss deserves a workup, not just reassurance

    After two or three consecutive losses, the textbook shifts from watchful waiting to systematic evaluation: parental karyotypes, uterine anatomy, antiphospholipid antibodies, and selected other tests. Some causes—antiphospholipid syndrome in particular—have evidence-based treatments that change outcomes.

    The idea

    Recurrent loss is a defined clinical entity with a finite, evidence-based evaluation. Not every test on the market is worth doing; the workup targets causes with proven treatments. The antiphospholipid antibody finding matters because heparin plus low-dose aspirin has trial support for improving live birth rates in that subgroup.

    Try this: After two consecutive losses, ask for a structured recurrent-loss workup rather than 'just try again.'

13. 13Ch. 39 (Gastrointestinal complications)

    Nausea and vomiting of pregnancy: treat early, treat hard

    The textbook's approach to nausea and vomiting of pregnancy is to intervene before it becomes hyperemesis gravidarum. Waiting until dehydration and weight loss set in makes the condition harder to reverse. Early, aggressive, multimodal antiemetic treatment is the recommended posture.

    The idea

    The counterintuitive point is that mild symptoms deserve real treatment. Escalating therapy early—dietary changes, then antiemetics in combination—prevents the cascade into hyperemesis with its risks of weight loss, ketosis, and hospitalization. The condition is under-treated out of misplaced stoicism more often than over-treated.

    Try this: At the first sign of significant pregnancy nausea, ask for a written escalation plan rather than waiting until you can't keep fluids down.

14. 14Ch. 20 (Timing of delivery)

    Delivery timing is a balancing act with real costs on both sides

    Every decision about when to deliver balances two risks: leaving the fetus in an environment that's becoming hostile, and delivering into a world it isn't ready for. The textbook frames timing of delivery in complicated pregnancies as an explicit risk-benefit calculation, updated as gestational age advances.

    The idea

    Neither extreme is safe. The framework that organizes modern obstetrics is that gestational age shifts the risk calculus continuously, and the delivery decision should be revisited as new data—fetal testing, maternal status, ultrasound findings—arrives. 'Expectant management' is an active choice with its own monitoring requirements, not a default.

    Try this: If early delivery is proposed, ask what specifically has changed to tip the balance, and what the alternative expectant plan would monitor.

Obstetricians, maternal-fetal medicine fellows, midwives, and residents managing complicated pregnancies. Serious patients facing a high-risk pregnancy will also find it authoritative, if they bring patience and a glossary.

FAQ